Overview
| 别名 | Keratin; type I cytoskeletal 23; Cytokeratin-23; CK-23; Keratin-23; K23 |
| 基因名 | Cytokeratin-23 |
| UniProt ID | Q9C075 |
| 反应种属 | Human |
| 应用 | WB |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 7E1-I9-M7 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 48 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | WB-1:1000 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Keratin 23 (Cytokeratin-23) is an acidic type I intermediate filament protein that maintains the structural integrity of epithelial cells through heterotypic pairing with type II keratins. Beyond its mechanical role, Keratin 23 is involved in the DNA damage response, telomerase regulation via hTERT binding, and the promotion of epithelial-to-mesenchymal transition. It is expressed in pancreatic and ductular cells and plays a significant role in cell proliferation and migration. Clinically, Keratin 23 is frequently upregulated in aggressive cancers, most notably colon adenocarcinoma, where its expression correlates with irradiation resistance and poor patient survival. It also serves as a specific marker for ductular cells in alcoholic hepatitis, where its levels correlate with injury repair and collagen production. Knockdown of Keratin 23 has been shown to reduce tumor cell viability, highlighting its potential as a therapeutic target. |
检测原理